NCT05923099: An ongoing trial by LEO Pharma
This trial is ongoing. It must report results 4 days, 2 hours ago.
Full data
| Full entry on ClinicalTrials.gov | NCT05923099 |
|---|---|
| Title | A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-site, Parallel-group, Dose-finding Trial to Evaluate the Efficacy and Safety of Different Doses of Subcutaneously Administered LEO 138559 in Adult Subjects With Moderate-to-severe Atopic Dermatitis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 20, 2023 |
| Completion date | Dec. 11, 2024 |
| Required reporting date | Dec. 11, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |